Scintigraphy for detecting tumour necrosis factor- on the skin of patients with psoriatic arthritis

被引:2
|
作者
de Souza, S. A. L. [1 ]
Nentzinsky, V. [2 ]
do Carmo, C. C. M. [3 ]
Roimicher, L. [4 ]
da Fonseca, L. M. B. [1 ]
Gutfilen, B. [1 ]
机构
[1] Univ Fed Rio de Janeiro, Clementino Fraga Filho Univ Hosp, Dept Radiol, Rio De Janeiro, Brazil
[2] Univ Fed Rio de Janeiro, Clementino Fraga Filho Univ Hosp, Dept Rheumatol, Rio De Janeiro, Brazil
[3] Fluminense Fed Univ, Dept Radiol, Niteroi, RJ, Brazil
[4] Univ Fed Rio de Janeiro, Clementino Fraga Filho Univ Hosp, Dept Clin Med, Rio De Janeiro, Brazil
关键词
TRIAL;
D O I
10.1080/03009742.2016.1264627
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This study assessed the use of scintigraphy and magnetic resonance imaging (MRI) in identifying the presence and amount of tumour necrosis factor- (TNF-) in the joint or skin of patients with psoriatic arthritis, to guide the course of treatment more efficiently.Method: We compared the results of scintigraphy and MRI in two patients with psoriatic arthritis who underwent technetium-99m (Tc-99m)-anti-TNF- scintigraphy, and MRI 5days later.Results: Greater uptake of Tc-99m-anti-TNF- was observed in the left wrist and right second metacarpal in patient 1, and in the left ulnocarpal joint and distal interphalangeal joint of the left first metacarpal in patient 2. These results correlated with the MRI findings.Conclusions: Tc-99m-anti-TNF- scintigraphy may recognize the molecule involved in the inflammatory process. This may provide crucial information to help physicians make decisions about which drugs to use based on biological evidence, and which are cost-effective and appropriate for the treatment of choice. To the best of our knowledge, this is the first time that TNF- has been shown in the skin of a patient using diagnostic imaging methods.
引用
收藏
页码:377 / 380
页数:4
相关论文
共 50 条
  • [1] TUMOUR NECROSIS FACTOR INHIBITORS PERSISTENCE IN PSORIATIC ARTHRITIS PATIENTS
    Vieira-Sousa, E.
    Eusebio, M.
    Avila-Ribeiro, P.
    Khmelinskii, N.
    Machado, A. R.
    Martins Rocha, T.
    Bernardes, M.
    Santos-Faria, D.
    Leite Silva, J.
    Santos, H.
    Miguel, C.
    Carvalho, P.
    Costa, T.
    Teixeira, L.
    Meirinhos, T.
    Nero, P.
    Santos, M. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1584 - 1585
  • [2] Cutaneous leishmaniasis in a patient with psoriatic arthritis treated with tumour necrosis factor-α inhibitor
    Morsing, N., V
    Andreasen, C. M.
    Rasmussen, T. A.
    Moll, L. T.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2024, 53 (02) : 158 - 159
  • [3] Tumour necrosis factor-α polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis
    Al-Heresh, AM
    Proctor, J
    Jones, SM
    Dixey, J
    Cox, B
    Welsh, K
    McHugh, N
    RHEUMATOLOGY, 2002, 41 (05) : 525 - 530
  • [4] Plasma levels of tumour necrosis factor-α and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasis
    Johnson, C. M.
    Fitch, K.
    Merola, J. F.
    Han, J.
    Qureshi, A. A.
    Li, W. -Q.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (02) : 379 - 380
  • [5] Early effects of tumour necrosis factor α blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis
    Goedkoop, AY
    Kraan, MC
    Teunissen, MBM
    Picavet, DI
    de Rie, MA
    Bos, JD
    Tak, PP
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (07) : 769 - 773
  • [6] Relapse of psoriatic arthritis in patients with active psoriasis switched from tumour necrosis factor-α to interleukin-17A inhibitor
    Gisondi, P.
    Geat, D.
    Idolazzi, L.
    Girolomoni, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (03) : 624 - 626
  • [7] The Potential Effect of the Tumour Necrosis Factor-α Inhibitors on Vitamin D Status in Psoriatic Patients
    Ganzetti, Giulia
    Campanati, Anna
    Scocco, Vitangelo
    Brugia, Marina
    Tocchini, Massimo
    Liberati, Giulia
    Giulio-dori, Katia
    Brisigotti, Valerio
    Offidani, Annamaria
    ACTA DERMATO-VENEREOLOGICA, 2014, 94 (06) : 715 - 717
  • [8] Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist
    Wong, VK
    Lebwohl, MG
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (11) : 1505 - 1513
  • [9] Time and predictors of response to tumour necrosis factor-α blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort
    Eder, Lihi
    Chandran, Vinod
    Schentag, Catherine T.
    Shen, Hua
    Cook, Richard J.
    Gladman, Dafna D.
    RHEUMATOLOGY, 2010, 49 (07) : 1361 - 1366
  • [10] New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists
    Kary, S
    Worm, M
    Audring, H
    Huscher, D
    Renelt, M
    Sörensen, H
    Ständer, E
    Maass, U
    Lee, H
    Sterry, W
    Burmester, GR
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (03) : 405 - 407